373 related articles for article (PubMed ID: 21677670)
1. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.
Fridman JS; Scherle PA; Collins R; Burn T; Neilan CL; Hertel D; Contel N; Haley P; Thomas B; Shi J; Collier P; Rodgers JD; Shepard S; Metcalf B; Hollis G; Newton RC; Yeleswaram S; Friedman SM; Vaddi K
J Invest Dermatol; 2011 Sep; 131(9):1838-44. PubMed ID: 21677670
[TBL] [Abstract][Full Text] [Related]
2. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.
Punwani N; Scherle P; Flores R; Shi J; Liang J; Yeleswaram S; Levy R; Williams W; Gottlieb A
J Am Acad Dermatol; 2012 Oct; 67(4):658-64. PubMed ID: 22281165
[TBL] [Abstract][Full Text] [Related]
3. Topical Application of JAK1/JAK2 Inhibitor Momelotinib Exhibits Significant Anti-Inflammatory Responses in DNCB-Induced Atopic Dermatitis Model Mice.
Jin W; Huang W; Chen L; Jin M; Wang Q; Gao Z; Jin Z
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544712
[TBL] [Abstract][Full Text] [Related]
4. JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis.
Klaeschen AS; Nümm TJ; Herrmann N; Leib N; Maintz L; Sakai T; Wenzel J; Bieber T
J Allergy Clin Immunol; 2021 Jun; 147(6):2202-2212.e8. PubMed ID: 33338537
[TBL] [Abstract][Full Text] [Related]
5. Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor.
Punwani N; Burn T; Scherle P; Flores R; Shi J; Collier P; Hertel D; Haley P; Lo Y; Waeltz P; Rodgers J; Shepard S; Vaddi K; Yeleswaram S; Levy R; Williams W; Gottlieb AB
Br J Dermatol; 2015 Oct; 173(4):989-97. PubMed ID: 26123031
[TBL] [Abstract][Full Text] [Related]
6. IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: Implication for atopic dermatitis.
Bao L; Shi VY; Chan LS
Mol Immunol; 2012 Feb; 50(1-2):91-7. PubMed ID: 22226123
[TBL] [Abstract][Full Text] [Related]
7. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
Fridman JS; Scherle PA; Collins R; Burn TC; Li Y; Li J; Covington MB; Thomas B; Collier P; Favata MF; Wen X; Shi J; McGee R; Haley PJ; Shepard S; Rodgers JD; Yeleswaram S; Hollis G; Newton RC; Metcalf B; Friedman SM; Vaddi K
J Immunol; 2010 May; 184(9):5298-307. PubMed ID: 20363976
[TBL] [Abstract][Full Text] [Related]
9. JAK1/3 inhibition preserves epidermal morphology in full-thickness 3D skin models of atopic dermatitis and psoriasis.
Clarysse K; Pfaff CM; Marquardt Y; Huth L; Kortekaas Krohn I; Kluwig D; Lüscher B; Gutermuth J; Baron J
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):367-375. PubMed ID: 30357932
[TBL] [Abstract][Full Text] [Related]
10. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Quintás-Cardama A; Vaddi K; Liu P; Manshouri T; Li J; Scherle PA; Caulder E; Wen X; Li Y; Waeltz P; Rupar M; Burn T; Lo Y; Kelley J; Covington M; Shepard S; Rodgers JD; Haley P; Kantarjian H; Fridman JS; Verstovsek S
Blood; 2010 Apr; 115(15):3109-17. PubMed ID: 20130243
[TBL] [Abstract][Full Text] [Related]
11. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.
Parampalli Yajnanarayana S; Stübig T; Cornez I; Alchalby H; Schönberg K; Rudolph J; Triviai I; Wolschke C; Heine A; Brossart P; Kröger N; Wolf D
Br J Haematol; 2015 Jun; 169(6):824-33. PubMed ID: 25824483
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
[TBL] [Abstract][Full Text] [Related]
13. Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity.
Andrés RM; Hald A; Johansen C; Kragballe K; Iversen L
Exp Dermatol; 2013 May; 22(5):323-8. PubMed ID: 23614738
[TBL] [Abstract][Full Text] [Related]
14. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
[TBL] [Abstract][Full Text] [Related]
15. INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cells.
An HJ; Choi EK; Kim JS; Hong SW; Moon JH; Shin JS; Ha SH; Kim KP; Hong YS; Lee JL; Choi EK; Lee JS; Jin DH; Kim TW
Neoplasma; 2014; 61(1):56-62. PubMed ID: 24195509
[TBL] [Abstract][Full Text] [Related]
16. Studies on the anti-psoriasis effects and its mechanism of a dual JAK2/FLT3 inhibitor flonoltinib maleate.
Zhu J; Yang T; Tang M; Yang Z; Pei H; Ye H; Tang Y; Cheng Z; Lin P; Chen L
Biomed Pharmacother; 2021 May; 137():111373. PubMed ID: 33761599
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.
Works MG; Yin F; Yin CC; Yiu Y; Shew K; Tran TT; Dunlap N; Lam J; Mitchell T; Reader J; Stein PL; D'Andrea A
J Immunol; 2014 Oct; 193(7):3278-87. PubMed ID: 25156366
[TBL] [Abstract][Full Text] [Related]
18. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
Hermans MAW; Schrijver B; van Holten-Neelen CCPA; Gerth van Wijk R; van Hagen PM; van Daele PLA; Dik WA
Clin Exp Allergy; 2018 Nov; 48(11):1412-1420. PubMed ID: 29939445
[TBL] [Abstract][Full Text] [Related]
19. TSLP Down-Regulates S100A7 and ß-Defensin 2 Via the JAK2/STAT3-Dependent Mechanism.
Lee H; Ryu WI; Kim HJ; Bae HC; Ryu HJ; Shin JJ; Song KH; Kim TW; Son SW
J Invest Dermatol; 2016 Dec; 136(12):2427-2435. PubMed ID: 27498343
[TBL] [Abstract][Full Text] [Related]
20. Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling.
Rochman Y; Kashyap M; Robinson GW; Sakamoto K; Gomez-Rodriguez J; Wagner KU; Leonard WJ
Proc Natl Acad Sci U S A; 2010 Nov; 107(45):19455-60. PubMed ID: 20974963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
